Transforming Growth Factor Beta Signalling In Malignant Mesothelioma Growth And Collagen Production
Funder
National Health and Medical Research Council
Funding Amount
$509,917.00
Summary
Many cancers contain abundant connective tissue molecules called extracellular matrix (ECM) and data show that interaction of ECM with cells are important in the growth of cancers (1). Changes in expression of ECM and their receptors (integrins) have been associated with malignant changes in cells, enhanced tumour growth and resistance to chemotherapy (2,3). We have recently shown that inhibition of collagen, the most abundant ECM molecule produced by malignant mesothelioma (MM) cells, reduced M ....Many cancers contain abundant connective tissue molecules called extracellular matrix (ECM) and data show that interaction of ECM with cells are important in the growth of cancers (1). Changes in expression of ECM and their receptors (integrins) have been associated with malignant changes in cells, enhanced tumour growth and resistance to chemotherapy (2,3). We have recently shown that inhibition of collagen, the most abundant ECM molecule produced by malignant mesothelioma (MM) cells, reduced MM growth. How cancer cells regulate ECM production and control their growth is unclear but strong evidence suggests the growth factor transforming growth factor-beta (TGFB) plays an important role. We and others showed that MM cells secrete all forms (1-3) of TGFB, and TGFB1,2-like activity has been reported in pleural effusions from MM (4,5). All TGFB forms stimulate MM cells to grow and make ECM (6,7). We showed that high levels of collagen produced by MM are enhanced by TGFB. Small molecules called antisense oligonucleotides (AO) which blocked production of TGFB2 by cells, reduced MM cell growth in soft agar, a characteristic of cancer, and partially blocked MM growth in animal models (4,6). This was supported by studies using soluble TGFB type II receptors, which blocks TGFB1,3 (8), and our studies using TGFB2 specific antibodies, as both studies reduced tumour growth. These findings support a role for TGFB in MM growth. However, all TGFB forms can promote cell grow and collagen synthesis and therefore ways to block all TGFB forms are required to ensure maximal effect. This study will examine the effect of blocking common downstream signalling pathways of all three TGFB isoforms on MM collagen production and tumour growth. These pathways are activated when TGFB binds to its receptors sending messages to the nucleus of the cell to make collagen or grow. By identifying which TGFB signalling pathway is important, we may be able to design novel therapeutic approaches to help treat patients with this disease.Read moreRead less
Activation Transcription Factor-4: Novel Regulator Of Smooth Muscle Cell Repair And Intimal Thickening Through Tenascin C
Funder
National Health and Medical Research Council
Funding Amount
$228,313.00
Summary
CVD represents the most important cause of morbidity and mortality in the world, accounting for 35% of all deaths in Australia. Smooth muscle cell growth accounts for a range of vascular proliferative disorders. This project focuses on understanding the role of ATF-4 as a new key regulator of SMC proliferation and intimal thickening in injured vessels. Moreover, strategies targeting ATF-4 will facilitate future therapeutic strategies to control intimal thickening in patients with vascular diseas ....CVD represents the most important cause of morbidity and mortality in the world, accounting for 35% of all deaths in Australia. Smooth muscle cell growth accounts for a range of vascular proliferative disorders. This project focuses on understanding the role of ATF-4 as a new key regulator of SMC proliferation and intimal thickening in injured vessels. Moreover, strategies targeting ATF-4 will facilitate future therapeutic strategies to control intimal thickening in patients with vascular disease.Read moreRead less
This project will examine Activins, as contributing factors to the loss of lean and fat mass that is commonly observed in patients with advanced cancer, and evaluate the therapeutic prospects of administering novel engineered Activin inhibitors, to prevent Activin-induced disease.
Endocrine And Autocrine Regulation Of Breast Cancer Cell Growth By IGF Binding Protein-3 (IGFBP-3).
Funder
National Health and Medical Research Council
Funding Amount
$497,250.00
Summary
The insulin-like growth factor (IGF) system of growth factors and their regulatory proteins is essential for normal growth, but is also involved in a number of overgrowth disorders. Some clinical studies have shown that a high level of IGF-I in the blood increases the risk of breast cancer in some women, but if the protein which carries it in the circulation, IGFBP-3, is also high, the risk is reduced. It has therefore been suggested that IGFBP-3 may be useful in the treatment of breast cancer. ....The insulin-like growth factor (IGF) system of growth factors and their regulatory proteins is essential for normal growth, but is also involved in a number of overgrowth disorders. Some clinical studies have shown that a high level of IGF-I in the blood increases the risk of breast cancer in some women, but if the protein which carries it in the circulation, IGFBP-3, is also high, the risk is reduced. It has therefore been suggested that IGFBP-3 may be useful in the treatment of breast cancer. This is supported by laboratory studies showing that IGFBP-3 can inhibit cell division and stimulate cell death in many cell types, including breast cells. However, some cells are resistant to IGFBP-3 s inhibitory effects, and in some cases IGFBP-3 may stimulate cells to grow and divide. In fact, the amount of IGFBP-3 present in breast tumours is highest in the fastest growing, most malignant tumours, suggesting that IGFBP-3 may be stimulating their growth. Our laboratory data indicates that breast cancer cells which produce a high level of IGFBP-3 grow faster as tumours than cells which produce little or no IGFBP-3. We believe that this is because IGFBP-3 interacts with another hormone system which is involved in rapid tissue growth, the EGF system, and increases its ability to stimulate breast cells to divide. These observations raise a number of important questions: how does IGFBP-3 interact with the EGF system to stimulate tumour growth; does IGFBP-3 from the blood promote the growth of EGF-sensitive tumours; and can the interaction between IGFBP-3 and the EGF system be abolished, or switched from growth stimulatory to growth inhibitory, thus inhibiting tumour growth. Answering these questions will provide important new information regarding IGFBP-3 s stimulatory and inhibitory actions, and the role of endocrine IGFBP-3 in tumour growth, and have the potential to lead to the development of novel therapies involving IGFBP-3 for the treatment of overgrowth disorders.Read moreRead less
Novel GPCR Transactivation Of Serine Kinases In Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$386,565.00
Summary
All of biology and disease is based on cells receiving signals from hormones and growth factors via cell surface receptors. Cells integrate these signals to give a response which may be cell growth or the secretion of further hormones and growth factors. Signals from receptors can intersect to modify the response. This project will explore a new interaction we have discovered where a hormone activates its receptor to cause the activation of a growth factor receptor potentially providing new drug ....All of biology and disease is based on cells receiving signals from hormones and growth factors via cell surface receptors. Cells integrate these signals to give a response which may be cell growth or the secretion of further hormones and growth factors. Signals from receptors can intersect to modify the response. This project will explore a new interaction we have discovered where a hormone activates its receptor to cause the activation of a growth factor receptor potentially providing new drug targets in cardiovascular disease.Read moreRead less
Dr Gilchrist is a reproductive biologist studying factors that regulate the intrinsic quality of unfertilised eggs. He has developed a new form of hormone-free infertility treatment which he will test in a clinical trial over the next 5 years.
Investigating Follistatin-based Interventions For Long Term-protection Against Frailty Associated With Chronic Illness And Aging
Funder
National Health and Medical Research Council
Funding Amount
$987,169.00
Summary
Effective therapies are urgently needed to combat frailty arising from muscle wasting associated with chronic illness and aging. The proposed studies will investigate the prospects of developing novel short-term interventions that can confer long-term benefits for preventing and treating muscle wasting associated with chronic illness and advanced aging.
Characterization Of SgK269, A Master Regulator Of Growth Factor Receptor Signalling
Funder
National Health and Medical Research Council
Funding Amount
$623,751.00
Summary
Perturbed signaling within a cell can cause multiple diseases, including cancer. SgK269 is a scaffold protein involved in signaling and implicated in breast, colon and pancreatic cancer. By determining the signaling mechanism and function of the SgK269 scaffold, this work will provide novel and important insights into a key regulator of cell signaling, and reveal potential strategies for therapeutic targeting of the SgK269 scaffold that could be utilized in cancer treatment.